Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ruxolitinib”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT02974647
What this trial is testing

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

Who this might be right for
Lymphoma
Memorial Sloan Kettering Cancer Center 83
Testing effectiveness (Phase 2)Looking for participantsNCT07219576
What this trial is testing

Retifanlimab and Ruxolitinib In Solid Malignancies

Who this might be right for
Non Small Cell Lung CarcinomaRenal Cell Carcinoma
University of California, San Diego 40
Early research (Phase 1)Ended earlyNCT01730248
What this trial is testing

Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis

Who this might be right for
Myelofibrosis
Novartis Pharmaceuticals 63
Early research (Phase 1)Study completedNCT01433445
What this trial is testing

Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

Who this might be right for
Idiopathic MyelofibrosisPost Essential Thrombocythemia MyelofibrosisPost Polycythemia-Vera Myelofibrosis
Novartis Pharmaceuticals 61
Early research (Phase 1)Active Not RecruitingNCT05371964
What this trial is testing

Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

Who this might be right for
Myelofibrosis
Geron Corporation 30
Testing effectiveness (Phase 2)Ended earlyNCT01523171
What this trial is testing

Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib

Who this might be right for
Hematopoietic Neoplasm
Bristol-Myers Squibb 97
Testing effectiveness (Phase 2)Ended earlyNCT02553330
What this trial is testing

A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)

Who this might be right for
Alopecia Areata
Incyte Corporation 90
Post-approval studies (Phase 4)Looking for participantsNCT07101588
What this trial is testing

Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial

Who this might be right for
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Chinese PLA General Hospital 200
Testing effectiveness (Phase 2)Looking for participantsNCT03681561
What this trial is testing

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
Veronika Bachanova 54
Testing effectiveness (Phase 2)Looking for participantsNCT07228624
What this trial is testing

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Who this might be right for
Myelodysplastic/Myeloproliferative NeoplasmPrimary MyelofibrosisSecondary Myelofibrosis
Fred Hutchinson Cancer Center 50
Post-approval studies (Phase 4)Not Yet RecruitingNCT07498205
What this trial is testing

Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts

Who this might be right for
MyelofibrosisMyelofibrosis (MF)
SWOG Cancer Research Network 268
Not applicableStudy completedNCT05044026
What this trial is testing

A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Novartis Pharmaceuticals 1,012
Testing effectiveness (Phase 2)Active Not RecruitingNCT03801434
What this trial is testing

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Who this might be right for
BCR-JAK2 Fusion Protein ExpressionBlasts 20 Percent or Less of Peripheral Blood White CellsBlasts More Than 5 Percent of Bone Marrow Nucleated Cells+9 more
Stanford University 8
Very early researchLooking for participantsNCT06209606
What this trial is testing

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Oncotherapeutics 30
Not applicableEnded earlyNCT04331665
What this trial is testing

Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia

Who this might be right for
COVID-19Pneumonia
University Health Network, Toronto 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT04384692
What this trial is testing

Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis

Who this might be right for
Primary MyelofibrosisSecondary Myelofibrosis
Fred Hutchinson Cancer Center 53
Early research (Phase 1)Study completedNCT06555081
What this trial is testing

Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants

Who this might be right for
Healthy Participants
Incyte Corporation 168
Early research (Phase 1)Looking for participantsNCT07049575
What this trial is testing

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

Who this might be right for
Hidradenitis Suppurativa
Incyte Corporation 24
Large-scale testing (Phase 3)Active Not RecruitingNCT06832618
What this trial is testing

Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

Who this might be right for
Atopic Dermatitis
Incyte Corporation 159
Early research (Phase 1)Looking for participantsNCT06233110
What this trial is testing

Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD

Who this might be right for
Chronic Graft Versus Host Disease
Stefanie Sarantopoulos, MD, PhD. 30
Next Page